Skip to content

Clinical Study on the Treatment of Cancer-Related Fatigue Using Thunder-Fire Moxibustion

Clinical Study on the Treatment of Cancer-Related Fatigue Using Thunder-Fire Moxibustion

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000406
Enrollment
Unknown
Registered
2024-09-08
Start date
2024-10-01
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer-related fatigue

Interventions

waitlist control group:Standard Care
Thunder-fire moxibustion group:Standard Care + Thunder-Fire Moxibustion

Sponsors

Hospital of Chengdu University of Traditional Chinese Medicine,
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Complies with the diagnostic standards for Cancer-Related Fatigue as outlined in the International Classification of Diseases, 10th Edition (ICD-10); (2) Experiences moderate to severe levels of fatigue, quantified as a score of 4 or higher on the Piper Fatigue Scale; (3) Diagnosed with stage I to III breast cancer in female patients; (4) Aged between 18 and 80 years; (5) Achieves a score of 70 or higher on the Karnofsky Performance Status (KPS); (6) Has concluded treatment for breast cancer (including surgery, radiation, chemotherapy, or targeted therapy) at least three months prior, although ongoing hormone therapy for over four weeks is permitted.

Exclusion criteria

Exclusion criteria: (1) Currently pregnant or lactating; (2) Anemic conditions (hemoglobin levels below 110g/L); (3) Demonstrates abnormal thyroid function (free thyroxine levels exceeding 22pmol/L or thyroid-stimulating hormone levels above 5.0uIU/ml); (4) Exhibits liver function abnormalities (levels of aspartate aminotransferase or alanine aminotransferase exceeding twice the normal upper limit); (5) Shows renal function abnormalities (creatinine levels exceeding 1.5 times the upper limit of normal); (6) Suffers from psychiatric disorders or significant cognitive dysfunction.

Design outcomes

Primary

MeasureTime frame
Piper Fatigue Scale score;

Secondary

MeasureTime frame
Interleukin-6 (IL-6) and Interleukin-8 (IL-8);hypothalamic-pituitary-adrenal (HPA) axis-related hormone factors;Karnofsky Performance Scale score;

Countries

China

Contacts

Public ContactQiang Li

Department of Oncology , Hospital of Chengdu University of Traditional Chinese Medicine

2464346396@qq.com15882233050

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026